MARCoNS: The Hidden Nasal Bacteria Driving Chronic Fatigue, Brain Fog, and Mould Illness
By Alex Manos, MSc Nutrition, Functional Medicine Practitioner
If you've been struggling with unexplained fatigue, persistent brain fog, chronic sinus problems, or a general sense that your body just isn't recovering — no matter what you try — there may be a piece of the puzzle that most practitioners are missing.
It's called MARCoNS: Multiple Antibiotic Resistant Coagulase Negative Staphylococci.
This group of bacteria, residing deep in the nasal passages, is increasingly recognised within functional and integrative medicine as a significant driver of chronic illness — particularly in people who have been exposed to mould, biotoxins, or Lyme disease. In this article, I want to walk you through exactly what MARCoNS is, how it perpetuates a cycle of inflammation, and what a truly comprehensive approach to addressing it looks like.
What Is MARCoNS?
MARCoNS stands for Multiple Antibiotic Resistant Coagulase Negative Staphylococci. In plain language, these are a type of staphylococcal bacteria — the same family as the well-known Staph aureus — that have become resistant to multiple antibiotics and have taken up residence deep in the nasal cavity.
The "coagulase negative" part refers to the fact that, unlike Staph aureus, these bacteria don't produce the enzyme coagulase. This has historically led many clinicians to regard them as harmless or clinically insignificant. However, research published in the Annals of Clinical Microbiology and Antimicrobials tells a very different story: coagulase-negative staphylococci (CoNS) are widely responsible for laryngological diseases, with their pathogenicity linked to virulence determinants, biofilm formation, and genetic regulation mechanisms.
The key distinction with MARCoNS is that these bacteria don't simply colonise the outer nasal passages — they embed themselves deep within the sinuses, protected by a structure called a biofilm.
Why Biofilms Are the Real Problem
To understand why MARCoNS is so difficult to address, you need to understand biofilms.
A biofilm is essentially a fortress. It's a structured community of bacteria encased within a self-produced polymeric matrix — a combination of exopolysaccharides, proteins, and DNA that the bacteria generate to protect themselves from both the immune system and antimicrobial agents. Think of it as the bacteria building their own armoured shelter.
The existence of biofilms in chronic rhinosinusitis (CRS) was initially observed in patients using scanning electron microscopy in 2004. A complex polymicrobial community of both bacteria and fungi exists within biofilms in CRS, including Staphylococcus aureus, Pseudomonas aeruginosa, and coagulase-negative staphylococci.
The clinical consequence of this is significant. Biofilms are known to be highly resistant to antibiotics, which may trigger or maintain chronic inflammation in the sinonasal mucosa. In fact, biofilm-associated pathogens possess 10–1,000 times higher resistance to antibiotic treatment compared to planktonic (free-floating) cells. This is why standard antibiotics so often fail — even when they would technically be effective against the bacteria in an unprotected state, the biofilm renders them largely useless.
Research in Frontiers in Pharmacology confirmed that antibiotic therapy against biofilms is usually associated with relapse following cessation of treatment and may also have an adverse effect on normal commensal microflora.
Meanwhile, biofilm production was detected in over 88–90% of methicillin-resistant coagulase-negative staphylococci isolates studied — underscoring just how reliably these organisms use biofilm as a survival strategy.
The MARCoNS-MSH Connection: Where It Gets Really Important
Here is where MARCoNS becomes particularly relevant for those dealing with chronic illness — especially mould illness, CIRS (Chronic Inflammatory Response Syndrome), chronic fatigue, and Lyme disease.
The connection lies in a neuropeptide called alpha-Melanocyte Stimulating Hormone, or alpha-MSH.
Alpha-MSH is produced in the pituitary gland and hypothalamus and plays a critical role in immune regulation, inflammation control, and mucosal defence. Research published in BioMed Research International describes it as a unique endogenous molecule: alpha-MSH is a neuropeptide belonging to the melanocortin family, well known for its anti-inflammatory and antipyretic effects, and it shares several characteristics with antimicrobial peptides (AMPs).
Crucially, alpha-MSH has been shown to possess direct antibacterial activity against Staphylococci. Research demonstrated that alpha-MSH exhibited significant and rapid antibacterial activity against all studied strains including MRSA, and most importantly, exhibited antibacterial activity against staphylococcal biofilms.
This means that when alpha-MSH levels are healthy, the nasal mucosa has a degree of innate antimicrobial protection against exactly the kind of bacteria that cause MARCoNS.
The problem? Typically with CIRS there is a reduction in the normal levels of regulatory neuropeptides, especially MSH, and an elevation in at least one of the three inflammatory markers TGF-β1, C4a, and MMP-9.
In other words, the same inflammatory cascade triggered by mould exposure and biotoxin illness depletes the very neuropeptide that protects the nasal passages from MARCoNS colonisation. And once MARCoNS establishes itself, it further suppresses MSH levels — creating a vicious cycle. Research suggests that MARCoNS hemolysin enzymes cleave and inactivate MSH, further reducing the body's ability to regulate inflammation and protect itself from microbial colonisation.
Alpha-MSH has been shown to down-regulate inflammatory mucin expression in nasal epithelial cells by inhibiting NF-κB activity, and normal human nasal mucosa possesses the processing machinery to produce it. When this machinery is disrupted — as it is in biotoxin illness — the nasal environment becomes fertile ground for MARCoNS.
Who Is Most at Risk of MARCoNS?
MARCoNS is not found in the deep sinuses of people with healthy, intact immune and neuroimmune function. It appears almost exclusively in those with specific underlying vulnerabilities, most commonly:
Mould illness and CIRS: Exposure to water-damaged buildings and the mycotoxins they produce is the most common driver. The inflammatory cascade of CIRS depletes MSH, removing the mucosal protection that prevents deep nasal colonisation.
Chronic Lyme disease: The same biotoxin-driven inflammatory pathway seen in Lyme disease can deplete MSH and create conditions for MARCoNS to thrive.
Prolonged antibiotic use: Paradoxically, repeated or prolonged courses of antibiotics — often prescribed for the very infections associated with these conditions — can worsen the situation by selecting for more resistant bacterial strains and disrupting the nasal microbiome.
Symptoms Associated with MARCoNS
Because MARCoNS acts as a perpetuating driver of systemic inflammation rather than a simple localised infection, its symptoms extend far beyond the sinuses. Commonly reported presentations include:
Persistent fatigue that does not improve with rest
Brain fog, poor memory, and cognitive impairment
Chronic sinus congestion, pressure, or pain
Headaches
Heightened sensitivity to chemicals, foods, and the environment
Muscle aches and joint pain
Sleep disturbances
Mood dysregulation, including anxiety and depression
Hormonal imbalances
It is important to note that these symptoms overlap significantly with other chronic conditions — mould illness, ME/CFS, chronic Lyme, fibromyalgia, and autoimmune disorders. MARCoNS is not always present, but when it is, it functions as a perpetuating factor that can prevent recovery even when other aspects of treatment are addressed correctly.
The Nasal Microbiome: A Broader Lens
MARCoNS does not exist in isolation. It is one manifestation of a broader disruption to the nasal microbiome — the community of micro-organisms that normally inhabit the sinonasal passages and play an important role in immune regulation.
Research has established that chronic rhinosinusitis is associated with a significant reduction in the diversity of the sinus microbiota. CRS patients exhibit significantly reduced bacterial diversity compared with healthy controls, with multiple phylogenetically distinct lactic acid bacteria depleted alongside an increase in the relative abundance of pathogenic species.
One of the most intriguing findings in recent years concerns Lactobacillus sakei — a lactic acid bacterium identified as a potentially protective species in healthy sinuses. Lactobacillus sakei, identified from comparative microbiome analyses as a potentially protective species, defended against sinus infection in models where the native microbiota had been depleted.
Preclinical research confirmed this protective role: in antibiotic-treated murine models inoculated with pathogenic Corynebacterium tuberculostearicum, those also given Lactobacillus sakei showed sinus mucosal histology comparable to control animals with no significant differences in goblet cell numbers, while those without it showed profound goblet cell hyperplasia and mucin hypersecretion.
This tells us that addressing MARCoNS is not simply about eliminating a pathogen — it's about restoring a healthy nasal microbial ecosystem that has its own self-regulating, protective capacity.
Testing for MARCoNS
Testing involves a deep nasal swab — not a standard ENT swab, but one taken from deep within the nasal passages where the biofilm-protected bacteria reside. This culture is then sent to a specialist laboratory where it is assessed for:
The presence of coagulase-negative staphylococci
Antibiotic resistance profile
Biofilm production capacity
The presence of concurrent fungi or yeast
It is worth noting that MARCoNS testing is not routinely offered or interpreted within conventional NHS ENT settings, as the clinical significance of coagulase-negative staphylococci in the deep sinuses is not yet mainstream medical consensus. This is an area where functional and integrative medicine practitioners have led the clinical conversation.
A Functional Medicine Approach to MARCoNS
Treating MARCoNS effectively requires a multi-pronged approach that addresses the biofilm, the bacteria themselves, the underlying immune and neuroimmune environment, and the nasal microbiome more broadly.
1. Biofilm disruption
This is non-negotiable. Any antimicrobial approach — whether pharmaceutical or botanical — will have a very limited effect against MARCoNS unless the protective biofilm is first disrupted.
The chelating agent EDTA (ethylenediaminetetraacetate) is one of the most studied biofilm-disrupting agents in sinusitis research. EDTA has been found effective at both preventing biofilm formation and treating established biofilms, with research showing that EDTA and DNase together increase the susceptibility of biofilm-forming bacteria to antibiotic treatment.
2. Prescription-based nasal protocols (where applicable)
For many individuals within the CIRS framework, practitioners use a compounded nasal spray containing mupirocin, EDTA, and gentamicin — often referred to as BEG spray. The rationale is mechanistically sound: EDTA disrupts the biofilm matrix while the topical antibiotics target the exposed bacteria. This requires a prescription and should be supervised by a trained practitioner familiar with biotoxin illness.
3. Addressing the root cause: mould and biotoxin exposure
If MARCoNS has established itself because of mould illness or CIRS, treating the nasal bacteria alone will not result in lasting resolution. The underlying inflammatory drivers must be identified and addressed — which begins with accurate environmental assessment and, where necessary, proper mould remediation or relocation.
This is a point I cannot overstate in clinical practice. Continuing to live or work in a water-damaged building while attempting to treat MARCoNS is the clinical equivalent of bailing out a boat with the tap still running.
4. Supporting MSH and neuroimmune regulation
Since the MSH-MARCoNS cycle is central to the perpetuation of this problem, supporting the recovery of neuroimmune regulation is an important part of any comprehensive programme. This may include addressing upstream inflammatory drivers, optimising sleep architecture, supporting hypothalamic-pituitary function, and — in certain clinical protocols — the use of Vasoactive Intestinal Peptide (VIP) nasal spray, which is known to support MSH restoration in CIRS patients.
5. Nasal microbiome restoration
Given the research on the protective role of commensal nasal bacteria, restoring a healthy nasal microbial community is an emerging and important frontier in addressing chronic sinonasal dysbiosis. This is an area I follow closely in the evolving research landscape.
6. Broader immune and gut support
The gut microbiome exerts significant influence over systemic immune regulation, and gut dysbiosis is common in those with mould illness and CIRS. Addressing gut health, reducing inflammatory dietary drivers, and supporting mitochondrial function all contribute to the broader recovery trajectory.
Key Takeaways
MARCoNS is not a diagnosis that appears in standard medical textbooks or NHS referral pathways. But for practitioners working at the interface of chronic illness, mould toxicity, and immune dysfunction, it is a clinically meaningful and measurable contributor to patient suffering.
The evidence base here spans microbiology, neuroimmunology, and mucosal biology. What it tells us is this:
When the immune and neuroimmune environment is compromised — as it is in mould illness, CIRS, and chronic Lyme — the nasal passages become vulnerable to colonisation by antibiotic-resistant, biofilm-forming staphylococci. These bacteria then perpetuate the very immune dysregulation that allowed them to thrive. Breaking this cycle requires addressing biofilm, bacteria, and the underlying biology simultaneously.
If you are dealing with unexplained chronic symptoms and have a history of mould exposure, water-damaged buildings, persistent sinusitis, or a diagnosis of ME/CFS or chronic Lyme, MARCoNS may be a piece of your puzzle worth investigating.
References
Becker K, et al. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27(4):870–926.
Grosse-Onnebrink J, et al. Coagulase-negative staphylococci as a significant etiological factor of laryngological infections: a review. Ann Clin Microbiol Antimicrob. 2020;19(1):27.
Psaltis AJ, et al. The mechanisms of biofilm antibiotic resistance in chronic rhinosinusitis: A review. PMC. 2022.
Szczepanski S, et al. Biofilm and planktonic antibiotic resistance in patients with acute exacerbation of chronic rhinosinusitis. PMC. 2022.
Hall-Stoodley L, et al. Efficacy of a marine bacterial nuclease against biofilm forming microorganisms isolated from chronic rhinosinusitis. PMC. 2013.
Dowd SE, et al. Biofilm formation of methicillin-resistant coagulase negative staphylococci (MR-CoNS). PMC. 2017.
Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610.
Mishra J, et al. In vitro antimicrobial activity of alpha-melanocyte stimulating hormone against Staphylococcus aureus. PubMed. 2009.
Kim CH, et al. α-Melanocyte-stimulating hormone inhibits TNF-α-stimulated MUC5AC expression in human nasal epithelial cells. PubMed. 2010.
Ryan RW, et al. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. PMC. 2024.
Abreu NA, et al. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. PMC. 2012.
Marchiori C, et al. The role of probiotics in chronic rhinosinusitis treatment. PMC. 2021.
Cleland EJ, et al. Update on the role of the microbiome in chronic rhinosinusitis. Curr Treat Options Allergy. 2024.
Leid JG, et al. Photodynamic therapy of antibiotic resistant biofilms in a maxillary sinus model. PMC. 2013.
Psychogios P, et al. The biofilm matrix destabilizers, EDTA and DNaseI, enhance the susceptibility of nontypeable Haemophilus influenzae biofilms to treatment. PMC. 2015.
Drilling AJ, et al. Topical antibiofilm agents with potential utility in treatment of chronic rhinosinusitis. Front Pharmacol. 2022.
